Shares of Silence Therapeutics plc (LON:SLN) reached a new 52-week high on Wednesday . The company traded as high as GBX 610 ($7.97) and last traded at GBX 605 ($7.91), with a volume of 123017 shares traded. The stock had previously closed at GBX 540 ($7.06).
Separately, Peel Hunt reaffirmed a “buy” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th.
The stock has a market cap of $473.95 million and a PE ratio of -23.91. The business has a fifty day moving average of GBX 381.93 and a 200-day moving average of GBX 198.91.
In other Silence Therapeutics news, insider Dave Lemus acquired 4,000 shares of the stock in a transaction that occurred on Friday, October 4th. The stock was bought at an average cost of GBX 186 ($2.43) per share, with a total value of £7,440 ($9,721.68). Also, insider Steven Romano acquired 10,000 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The stock was acquired at an average cost of GBX 193 ($2.52) per share, with a total value of £19,300 ($25,218.87).
Silence Therapeutics Company Profile (LON:SLN)
Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.
Featured Article: How to trade on quiet period expirations
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.